Trabectedin
Reading tools
Approved by the FDA on 23 October 2015, Trabectedin (Yondelis®) is used after previous anthracycline-containing drug treatment for unresectable or distantly spread cancers originating in fat cells, liposarcoma and those originating in smooth muscle cells, leiomyosarcoma in affected patients.
Acting directly on DNA and its components, Trabectedin affects the cell's life cycle and causes destruction of cancer cells. Nausea, fatigue, vomiting, constipation, loss of appetite, diarrhea, swelling, difficulty breathing and headache are its most common side effects.
Was this article helpful?
Your feedback helps us improve our content.
Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.